- Eli Lilly’s experimental drug retatrutide produced large benefits in trials — participants lost about 28% of body weight and people with type 2 diabetes saw better blood sugar control.
- Beyond weight loss, the drug cut the severity of obstructive sleep apnea and substantially reduced knee osteoarthritis pain, suggesting broader health perks.
- Retatrutide is part of a hot race (Lilly vs. Novo Nordisk and others) to dominate the booming obesity/diabetes market, though a few rare heart-related events are still under review.
The news, distilled into what matters.
Get the full experience in the app — topics, comments, and audio summaries.